LIVE POLIO IRUS VACCINES

262 Efficacy-Laboratory Evidence
TABLE 27. ISOLATION OF ATTENUATED VIRUS OF POLIOMYELITIS TYPE 3 FROM CHILDREN (0-3 YRS.)
WITH CYTOPATHOGENIC AGENTS "CPA+" AND WITHOUT CYTOPATHOGENIC AGENTS "CPA-" DURING
THE 14 DAYS AFTER IMMUNIZATION
CHILDREN
1 +2 WEEKS
CPA CPA +
I
CPA-
3 +4 WEEKS
_
CPA+
Investigated 107 70 107 70
Virus isolated 40 2 34 14
Per cent 37 3 31 20
TABLE 28. ANTIBODY RESPONSE IN TRIPLE-NEGATIVE CHILDREN IMMUNIZED WITH TRIVALENT LIVE
VACCINE UNDER CONDITIONS OF MASS LATENT INFECTION WITH NON-POLIOMYELITIS ENTERIC VIRUSES
(CHILDREN'S HOMES L. AND R.)
DEVELOPED ANTIBODY TO
NUMBER
OF
CHILDREN
TYPE 1
No. %
TYPE 2
No. %
TYPE 3
No. %
One month after
first feeding
21
7 33.3
17 80.9
3 14.3
One month after
second feeding
18
7 38.9
15 83.3
7 38.9
the second feeding with trivalent live vaccine,
immunologic resistance of the intestinal tract of
the vaccinated was tested separately to Type 1,
Type 2, and Type 3 vaccine viruses. Owing to
considerable spread of non-poliomyelitis enteric
viruses, the results of this test could be considered
valid only in five cases for Type 1, in
nine cases for Type 2, and in three cases for
Type 3. In five children possessing no Type 1
antibody before vaccination, Type 1 vaccine virus
multiplied after primary vaccination during four
to five weeks, and Type 1 antibody developed in
titers 1:32, 1:128 in four children only. On testing
immunological resistance of the intestinal
tract three months after the second feeding, one
episode of Type 1 virus excretion was observed
in one child, V.P., 10 months old (101 . 7 TCD,,
per gram), who had previously developed Type
1 antibody to the titer 1:128. Child P.T., 23
months old, who had no antibody despite extensive
multiplication of Type 1 virus after first ingestion
of the vaccine, exhibited immunological
resistance of the intestinal tract to Type 1 virus.
Evidently, in this case, immunological resistance
of the intestinal tract developed without concurrent
production of serum antibody.
Eight out of nine children without pre-vaccination
Type 2 antibody, excreting vaccine virus during
four weeks after primary feeding, showed no
multiplication of Type 2 vaccine virus. Child
I.K., two years old, who had previously excreted
Type 2 vaccine virus for one week and developed
Type 2 antibody in the titer 1:16 after the test
for the intestinal tract resistance, had one episode
of Type 2 virus excretion with 103 TCD,, 0 of virus
per gram of feces.
In a special investigation of immunologic resistance
in children who had had poliomyelitis,
one episode of homologous Type 1 virus excre-